Jinhai Medical Technology Limited (Stock Code: 2225) announced that Li Bin, aged 52, has been appointed as an executive director and co-chairman of the board with effect from 3 February 2026.

According to the announcement, Li Bin brings over 20 years of enterprise and business management experience. He founded and has been chairing Shanghai Anbaida Investment Management Consulting Co., Ltd. since April 2005, focusing on sales of in vitro diagnostic reagents. He has also been a first-tier distributor of Roche In Vitro Diagnostics in Shanghai since April 2004.

As stated, Li Bin is interested in 40,000,000 shares of Jinhai Medical Technology Limited under the Hong Kong Securities and Futures Ordinance. There is a three-year service contract between Li Bin and the company, under which he will receive a fixed monthly director’s fee of HK$200,000. He is subject to retirement by rotation and re-election at annual general meetings in accordance with the company's Articles of Association.

Following this announcement, the board of Jinhai Medical Technology Limited comprises four executive directors, one non-executive director, and three independent non-executive directors.